{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:06:05Z","timestamp":1787785565154,"version":"build-2784847793"},"reference-count":25,"publisher":"Termedia Sp. z.o.o.","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reumatologia"],"published-print":{"date-parts":[[2021,9,2]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Osteoporosis is the most common bone tissue disease and it is characterized by a re\ufffdduced bone mineral density (BMD). The main physiopathological mechanisms converge on the un\ufffdcoupling between bone formation and resorption, thus leading to an enhanced risk of fractures. \nSeveral papers have documented the inverse relationships linking high inflammatory cytokines, anti\ufffdcitrullinated protein antibodies, rheumatoid factor, and BMD in rheumatoid arthritis (RA). Rituximab \n(RTX) is a chimeric monoclonal antibody directed against the CD20 receptor of B cells. Since the \nFood and Drug Administration approved it for RA in 2006, there have been many clinical experiences \nregarding its use. Nevertheless, few studies evaluate the effect of rituximab on BMD. RA is a disease \ncharacterized by immune dysfunction with high levels of inflammatory cytokines, autoantibodies, \nand it is reasonable that a B cell depleting therapy could restore a physiological cytokine balance, \nthus exerting an osteoprotective effect on the bone tissue. The purpose of this paper is to highlight \nany difference in BMD and to assess differences in body composition over a retrospective 18-month \nfollow-up period after RTX treatment with a B cell depleting therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Material and methods<\/jats:title><jats:p>We analyzed by dual energy X-ray absorptiometry BMD expressed as g\/cm2\nand body composition modifications over 18 months with RTX treatment of 20 postmenopausal RA \npatients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>After eighteen months of therapy with RTX, a statistically significant increase in vertebral \n(L1\u2013L4) BMD and the stability of femoral BMD were documented.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Rituximab is associated with an improvement of vertebral and preservation of femo\ufffdral BMD, suggesting a bone-sparing effect due to B cell depletion. Furthermore, patients displayed \na redistribution of fat masses toward the hip region.<\/jats:p><\/jats:sec>","DOI":"10.5114\/reum.2021.108430","type":"journal-article","created":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T11:23:00Z","timestamp":1631704980000},"page":"206-210","source":"Crossref","is-referenced-by-count":19,"title":["Bone-sparing effects of rituximab and body composition analysis \nin a\u00a0cohort of postmenopausal women affected by rheumatoid \narthritis \u2013 retrospective study"],"prefix":"10.5114","volume":"59","author":[{"given":"Suhel Gabriele","family":"Al Khayyat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Falsetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Conticini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"D'Alessandro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bellisai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Gentileschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Baldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Bardelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Cantarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Frediani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3061","published-online":{"date-parts":[[2021,8,17]]},"reference":[{"key":"ref-782999","doi-asserted-by":"publisher","DOI":"10.1002\/art.27584"},{"key":"ref-783000","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32112-3"},{"key":"ref-783001","doi-asserted-by":"publisher","DOI":"10.4081\/reumatismo.2014.785"},{"key":"ref-783002","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3669"},{"key":"ref-783003","doi-asserted-by":"publisher","DOI":"10.1172\/JCI60975"},{"key":"ref-783004","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01851"},{"key":"ref-783005","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a009520"},{"key":"ref-783006","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004497"},{"key":"ref-783007","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2010.02.022"},{"key":"ref-783008","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0201527"},{"key":"ref-783009","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmrj.2011.02.017"},{"key":"ref-783010","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00579.2003"},{"key":"ref-783011","unstructured":"Frediani B, Falsetti P, Bisogno S, et al. Effects of high dose methylprednisolone pulse therapy on bone mass and biochemical markers of bone metabolism in patients with active rheumatoid arthritis: A\u00a012-month randomized prospective controlled study. J Rheumatol 2004; 31: 1083\u20131087."},{"key":"ref-783012","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2014.121"},{"key":"ref-783013","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0188454"},{"key":"ref-783014","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-016-3769-2"},{"key":"ref-783015","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.12189"},{"key":"ref-783016","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12771"},{"key":"ref-783017","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.895116"},{"key":"ref-783018","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20111675"},{"key":"ref-783019","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.13800"},{"key":"ref-783020","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00576"},{"key":"ref-783021","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2012.120"},{"key":"ref-783022","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000129790.00318.a3"},{"key":"ref-783023","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140690"}],"container-title":["Rheumatology"],"original-title":[],"link":[{"URL":"https:\/\/reu.termedia.pl\/pdf-140973-85993","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/reu.termedia.pl\/pdf-140973-85993","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T08:00:19Z","timestamp":1674806419000},"score":1,"resource":{"primary":{"URL":"https:\/\/reu.termedia.pl\/Bone-sparing-effects-of-rituximab-and-body-composition-analysis-r-nin-a-cohort-of,140973,0,2.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,17]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"alternative-id":["140973"],"URL":"https:\/\/doi.org\/10.5114\/reum.2021.108430","relation":{},"ISSN":["0034-6233","2084-9834"],"issn-type":[{"value":"0034-6233","type":"print"},{"value":"2084-9834","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,17]]}}}